Candel Therapeutics: Funding, Investors & Team (Oct 2026)
Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.
Candel Therapeutics has raised $362M across 5 funding rounds on record, the most recent an undisclosed round of $100M announced in Feb 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Candel Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Candel Therapeutics Funding Rounds
Candel Therapeutics raised $25.0M in a Post-IPO Debt announced in Mar 2022.
2.8 years later, an undisclosed round of $92.0M was announced in Dec 2024.
6 months later, an undisclosed round of $15.0M was announced in Jun 2025.
4 months later, an undisclosed round of $130M was announced in Oct 2025.
4 months later, an undisclosed round of $100M was announced in Feb 2026.
Candel Therapeutics Founders and Leadership Team
Contact details for the Candel Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Candel Therapeutics Funding Compared to Other Biotechnology Startups
Candel Therapeutics' latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Candel Therapeutics in Biotechnology and Needham
Companies Similar to Candel Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Candel Therapeutics Funding FAQs
What does Candel Therapeutics do?
Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.
How much funding has Candel Therapeutics raised?
Candel Therapeutics has raised $362M across 5 rounds on record. The most recent is an undisclosed round of $100M announced in Feb 2026.
When did Candel Therapeutics last raise funding?
Candel Therapeutics' most recent funding round on record is an undisclosed round of $100M, announced in Feb 2026.
Who founded Candel Therapeutics?
FundedIQ lists Estuardo Aguilar Cordova (Founder) at Candel Therapeutics.
Who is the CEO of Candel Therapeutics?
Estuardo Aguilar-Cordova is listed as CEO at Candel Therapeutics.
Where is Candel Therapeutics headquartered?
Candel Therapeutics is based in Needham, Massachusetts, United States.
How many employees does Candel Therapeutics have?
Candel Therapeutics is in the 11-50 employee band.
How does Candel Therapeutics' funding compare to other Biotechnology startups?
Candel Therapeutics' latest round of $100M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Candel Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Candel Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.